Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non-cash Items (2020 - 2025)

Historic Non-cash Items for Insight Molecular Diagnostics (IMDX) over the last 4 years, with Q3 2025 value amounting to $306000.0.

  • Insight Molecular Diagnostics' Non-cash Items rose 3362.45% to $306000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $306000.0, marking a year-over-year increase of 3362.45%. This contributed to the annual value of $19.1 million for FY2021, which is 13580.25% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Non-cash Items stood at $306000.0 for Q3 2025, which was up 3362.45% from $390000.0 recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Non-cash Items high stood at $19.1 million for Q4 2021, and its period low was $51.0 during Q2 2024.
  • Moreover, its 3-year median value for Non-cash Items was $279000.0 (2025), whereas its average is $2.9 million.
  • Within the past 5 years, the most significant YoY rise in Insight Molecular Diagnostics' Non-cash Items was 76460588.24% (2025), while the steepest drop was 3362.45% (2025).
  • Insight Molecular Diagnostics' Non-cash Items (Quarter) stood at $19.1 million in 2021, then tumbled by 98.8% to $229000.0 in 2024, then surged by 33.62% to $306000.0 in 2025.
  • Its last three reported values are $306000.0 in Q3 2025, $390000.0 for Q2 2025, and $279000.0 during Q1 2025.